![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/22/2934023/0/en/Telix-2024-Half-Year-Results-Strong-Commercial-Revenue-and-Profit-Growth-to-Support-Strategic-Priorities.html
https://www.globenewswire.com/news-release/2024/07/29/2920202/0/en/Expanded-Access-Program-Opens-in-the-U-S-for-TLX101-CDx-Telix-s-Investigational-Glioma-Brain-Cancer-Imaging-Agent.html
https://www.globenewswire.com/news-release/2024/07/23/2917666/0/en/FDA-Accepts-Telix-NDA-for-New-Prostate-Cancer-Imaging-Agent.html
https://www.globenewswire.com/news-release/2024/07/17/2914972/0/en/Q2-2024-Revenue-and-Business-Highlights-Guidance-Upgrade.html
https://www.globenewswire.com/news-release/2024/07/11/2911505/0/en/Telix-Welcomes-CMS-Proposal-to-Improve-Payment-for-Specialised-Diagnostic-Radiopharmaceuticals.html
https://telixpharma.com/news-views/telix-elects-to-withdraw-from-proposed-u-s-listing/
https://www.globenewswire.com/news-release/2024/06/05/2893759/0/en/Telix-Announces-Launch-of-Proposed-Initial-Public-Offering-in-the-United-States.html
https://www.globenewswire.com/news-release/2024/06/02/2891867/0/en/Telix-Completes-TLX250-CDx-Zircaix-BLA-Submission-for-Kidney-Cancer-Imaging.html
https://www.globenewswire.com/news-release/2024/05/30/2891221/0/en/Telix-Announces-Positive-rPFS-Data-from-ProstACT-SELECT-Trial-of-TLX591-rADC-Therapy-Candidate-in-Prostate-Cancer.html
https://www.prnewswire.com/news-releases/telix-announces-positive-rpfs-data-from-prostact-select-trial-of-tlx591-radc-therapy-candidate-in-prostate-cancer-302160145.html